Abstract
1 Observations were made in five subjects who exercised before and at 2, 3, 6, 8, 24, 33 and 48 h after the oral administration of placebo and 5, 10, 20 and 40 mg betaxolol. 2 The exercise heart rate remained constant at all times after the placebo. All doses of betaxolol significantly reduced the exercise tachycardia at all times. The maximum effect (34.4 +/- 2.2%) occurred after 40 mg. 3 There was a small decline in effect from the peak to 24 h when 40 mg produced a 23.3 +/- 2.7% reduction and a further decline to 48 h when there was a 14.6 +/- 1.8% reduction. 4 Plasma levels of betaxolol were measured in these studies. The peak plasma concentration occurred between 3 and 8 h with different doses. The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h. 5 The effects of 40 mg betaxolol, 200 mg atenolol, 160 mg propranolol, 160 mg oxprenolol, 400 mg sotalol and placebo on an exercise tachycardia were compared in five subjects who received all treatments in random order. 6 There was no significant difference in the maximum reduction produced in an exercise tachycardia by the different drugs. 7 The effect of all drugs decreased with time. The effect of oxprenolol had worn off a...Continue Reading
References
Jun 9, 1976·Journal of Chromatography·P H Degen, W Riess
Nov 1, 1976·Clinical Pharmacology and Therapeutics·H C BrownR G Shanks
Aug 1, 1977·British Journal of Clinical Pharmacology·D G McDevitt
Aug 1, 1979·Journal of Chromatography·G BianchettiP L Morselli
May 27, 1978·British Medical Journal·T ReybrouckE Meulepas
Nov 27, 1978·European Journal of Clinical Pharmacology·A P Douglas-JonesA Lee
Jun 1, 1979·British Journal of Clinical Pharmacology·A BobikG Jackman
Aug 1, 1978·British Journal of Clinical Pharmacology·J McAinshJ Young
Oct 1, 1976·British Journal of Clinical Pharmacology·M WilsonT Morgan
Mar 22, 1976·European Journal of Clinical Pharmacology·H C BrownR G Shanks
Jan 1, 1970·Clinical Pharmacology and Therapeutics·D G ShandJ A Oates
Jan 1, 1980·British Journal of Clinical Pharmacology·W J LeaheyR G Shanks
Jun 1, 1980·European Journal of Clinical Pharmacology·W J LeaheyR G Shanks
Dec 1, 1976·British Journal of Clinical Pharmacology·S G CarruthersD G McDevitt
Feb 1, 1974·British Journal of Clinical Pharmacology·C M Kaye
Citations
Aug 1, 1990·Journal of Clinical Pharmacology·W H FrishmanD Behrman
Apr 1, 1992·Journal of Clinical Pharmacology·R L WilliamsL B Hogan
Jan 1, 1983·European Journal of Clinical Pharmacology·R Palminteri, G Kaik
Jan 1, 1990·Pharmacology & Therapeutics·T H Pringle, J G Riddell
Jul 5, 2001·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·E Vainio-JylhäR Huupponen
Jul 1, 1990·British Journal of Clinical Pharmacology·N A IrvineD G McDevitt
Feb 1, 1991·British Journal of Clinical Pharmacology·B J LipworthD G McDevitt
Mar 18, 1999·Australian and New Zealand Journal of Ophthalmology·J L Rait
Dec 1, 1987·Journal of Clinical Pharmacy and Therapeutics·J V Okopski
Sep 29, 2004·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·S M Al-SaidanR S Karthikeyan
Mar 1, 1987·American Heart Journal·A S IskandrianC Schenk
Aug 1, 1987·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J H BauerA Lau
May 1, 1990·Angiology·M A AlpertR J Morgan
Jan 1, 1984·Biomedical Mass Spectrometry·P HermannJ P Thenot
Jan 1, 1982·European Journal of Clinical Pharmacology·J T Salonen, R Palminteri
Jul 5, 2012·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Joanna LazniewskaTeresa Gabryelak
Apr 1, 1985·British Journal of Clinical Pharmacology·J G RiddellR G Shanks
Feb 1, 1987·Journal of Clinical Pharmacology·G P ReamsA Lau
Feb 1, 1985·British Journal of Clinical Pharmacology·J M PatrickA T Birmingham
Apr 1, 1987·British Journal of Clinical Pharmacology·T H PringleR G Shanks